Suppr超能文献

对接受预先移植与透析后联合胰腺-肾脏移植的I型糖尿病患者的结果和发病率进行比较分析。

A comparative analysis of results and morbidity in type I diabetics undergoing preemptive versus postdialysis combined pancreas-kidney transplantation.

作者信息

Stratta R J, Taylor R J, Ozaki C F, Bynon J S, Miller S A, Knight T F, Fischer J L, Neumann T V, Wahl T O, Duckworth W C

机构信息

Department of Surgery, University of Nebraska Medical Center, Omaha 68198-3280.

出版信息

Transplantation. 1993 May;55(5):1097-103. doi: 10.1097/00007890-199305000-00031.

Abstract

Although combined pancreas-kidney transplantation (PKT) has become a valid treatment option for selected type I diabetics, the timing of PKT relative to the degree of nephropathy remains controversial. We analyzed results and morbidity in 30 type I diabetics undergoing PKT after starting dialysis (PKT:D) versus 31 type I diabetics undergoing PKT prior to dialysis (PKT:ND). The two groups were similar with the respect to age, duration and severity of diabetes, gender, race, preservation time, retransplants, sensitization, HLA-matching, and CMV status. The mean preoperative serum creatinine was higher in the PKT:D group (9.9 +/- 3.4 vs. 3.9 +/- 1.9 mg/dl PKT:ND, P < 0.01). All patients were managed with quadruple immunosuppression with OKT3 induction. Actuarial patient survival is 100% (PKT:D) and 96.8% (PKT:ND). Renal and pancreas allograft survival are 97% and 93%, respectively, in both groups. The incidence of rejection, infection, operative complications, reflux pancreatitis, and total hospital days was similar in both groups. Long-term renal and pancreas allograft function and quality of life were like-wise comparable. No adverse coagulation or immunologic effects were noted in the PKT:ND group. Rehabilitation potential favored the PKT:ND group. PKT can be performed safely and effectively in the absence of uremia. In selected type I diabetics with significant nephropathy, we believe that PKT is the best treatment option and need not be considered as preemptive, especially in view of increasing waiting times and the variable progressive nature of diabetic complications.

摘要

尽管胰肾联合移植(PKT)已成为特定I型糖尿病患者的有效治疗选择,但PKT相对于肾病程度的时机仍存在争议。我们分析了30例开始透析后接受PKT(PKT:D)的I型糖尿病患者与31例透析前接受PKT(PKT:ND)的I型糖尿病患者的结果和发病率。两组在年龄、糖尿病病程和严重程度、性别、种族、保存时间、再次移植、致敏、HLA配型和巨细胞病毒状态方面相似。PKT:D组术前平均血清肌酐较高(9.9±3.4 vs. 3.9±1.9 mg/dl,PKT:ND,P<0.01)。所有患者均采用OKT3诱导的四联免疫抑制治疗。患者精算生存率在PKT:D组为100%,在PKT:ND组为96.8%。两组的肾和胰腺同种异体移植生存率分别为97%和93%。两组的排斥反应、感染、手术并发症、反流性胰腺炎发生率和总住院天数相似。长期肾和胰腺同种异体移植功能及生活质量同样具有可比性。PKT:ND组未观察到不良凝血或免疫效应。康复潜力有利于PKT:ND组。在无尿毒症的情况下,PKT可以安全有效地进行。对于选定的有严重肾病的I型糖尿病患者,我们认为PKT是最佳治疗选择,不必视为抢先治疗,特别是考虑到等待时间增加以及糖尿病并发症的可变进展性质。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验